CNSP
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. (CNSP) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 47.4, with 0/3 trend checks passing.
CNSP with MA50 and MA200
Key levels & signals
CNS Pharmaceuticals, Inc. (CNSP) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $4.68, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 9.4% and below the 200-day moving average by 12.5%.
CNSP currently has an RSI reading of 47.4, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing CNSP next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
CNSP shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about CNSP
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.